Prize Contingency Management for Cocaine-Dependent Methadone Patients

Sponsor
UConn Health (Other)
Overall Status
Completed
CT.gov ID
NCT01401270
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
280
1
6
78
3.6

Study Details

Study Description

Brief Summary

The investigators will randomize 300 cocaine-dependent methadone patients to 1 of 6 conditions: (a) a control group, (b) a contingency management condition that arranges a 100% probability of winning a prize with each draw and has 3 prize categories, (c) a contingency management condition that arranges a 31% probability of winning and has 3 prize categories, (d) a contingency management condition that arranges a 100% probability of winning and has 7 prize categories, (e) a contingency management condition that arranges a 31% probability of winning and has 7 prize categories, or (f) usual prize contingency management with a 50% probability of winning from 3 prize categories. Magnitudes of reinforcement will be identical across conditions, but lower overall probability conditions arrange for greater chances of winning larger magnitude prizes. The investigators expect that the new contingency management conditions will reduce cocaine use relative to the control condition, that 31% probability conditions will decrease drug use relative to 100% conditions, and that 7-prize category conditions will reduce drug use compared to 3-prize category conditions. In addition, the 31%/7-category condition is expected to be most efficacious. Results will be instrumental for further developing prize contingency management to improve outcomes of cocaine-dependent methadone patients.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: prize contingency management
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
280 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prize Contingency Management for Cocaine-Dependent Methadone Patients
Actual Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
May 1, 2018
Actual Study Completion Date :
May 1, 2018

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Treatment Group A

Standard Care

Experimental: Treatment Group B

100% probability of winning a prize with each draw and has 3 prize categories

Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group C

31% probability of winning and has 3 prize categories

Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group D

100% probability of winning and has 7 prize categories

Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group E

31% probability of winning and has 7 prize categories

Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Experimental: Treatment Group F

usual prize contingency management with a 50% probability of winning from 3 prize categories

Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

Outcome Measures

Primary Outcome Measures

  1. longest continuous period of cocaine abstinence [three months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age > 18 years

  • current DSM-IV diagnosis of cocaine dependence

  • enrolled at the clinic for >3 months

  • on a stable dose of methadone (no changes) for >1 month and not requesting a dose alteration

  • submitted >1 clinic cocaine positive sample in the last 6 months

  • English speaking

  • pass a quiz related to understanding the informed consent form

Exclusion Criteria:
  • serious, uncontrolled psychiatric illness

  • significant cognitive impairment

  • in recovery from pathological gambling

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Connecticut Health Center Farmington Connecticut United States 06030

Sponsors and Collaborators

  • UConn Health
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Sheila M Alessi, Ph.D., UConn Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sheila Alessi, Associate Professor, UConn Health
ClinicalTrials.gov Identifier:
NCT01401270
Other Study ID Numbers:
  • 10-256-2
  • R01DA013444
First Posted:
Jul 25, 2011
Last Update Posted:
Mar 13, 2019
Last Verified:
Mar 1, 2019
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2019